Bioenvision to Host First Quarter 2006 Financial Results Conference Call
November 10 2005 - 4:30PM
Business Wire
Bioenvision (NASDAQ NM: BIVN) today announced that the Company will
host a conference call with the financial community to discuss the
first quarter 2006 financial results on Monday, November 14, 2005
at 8 a.m. EST. To participate in the live call by telephone, please
dial 877-825-5811 from the U.S. and Canada or 973-582-2767 from
outside the U.S. A telephone replay of the call will be available
beginning at 10:00 a.m. EST November 14th until 11:59 p.m. EST
November 28th by dialing 877-519-4471 or 973-341-3080 and entering
reservation number 6701150. Those interested in listening to the
conference call live via the Internet may do so by visiting
Bioenvision's web site at www.bioenvision.com. To listen to the
live call, please go to the web site 15 minutes prior to its start
to register, download, and install the necessary audio software. A
replay will be available on the web site for 14 days. About
Bioenvision Bioenvision's primary focus is the acquisition,
development and distribution of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products
for the treatment of cancer, including: Clofarabine (in
co-development with Genzyme Corporation), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products
in clinical trials. Bioenvision is also developing anti-infective
technologies, including Virostat for hepatitis-C and the OLIGON
technology; an advanced biomaterial that has been incorporated into
various FDA approved medical devices. For more information on
Bioenvision please visit our web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024